According to a recent LinkedIn post from AvenCell Therapeutics Inc, the company has dosed the first patient in its Phase I QUADvance study evaluating AVC-203. The post describes AVC-203 as a CRISPR-engineered, allogeneic, dual-targeting CD19/CD20 switchable CAR-T therapy and characterizes it as the first of its kind to reach clinical testing.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The LinkedIn post emphasizes the transition of this program from preclinical work into the clinic and directs readers to a full press release for additional detail. For investors, first-patient dosing in a Phase I trial typically marks a key value-inflection point, suggesting progression of AvenCell’s pipeline and the potential to generate early safety and activity data in hematologic oncology.
If the therapy’s switchable, dual-targeting design demonstrates a favorable risk-benefit profile, AvenCell could strengthen its competitive position within the emerging allogeneic CAR-T segment. However, as with all first-in-human studies, clinical, regulatory, and manufacturing risks remain high, and any financial or partnership impact will depend on forthcoming trial results and detailed disclosures beyond the LinkedIn summary.